PKSI-527 – 5 mg

Brand:
Cayman
CAS:
128837-71-8
Storage:
-20
UN-No:
Non-Hazardous - /

PKSI-527 is an inhibitor of plasma kallikrein (Ki = 0.81 μM).{39442} It is selective for plasma kallikrein over glandular kallikrein, plasmin, thrombin, urokinase, and Factor Xa (Kis = >500, 390, >500, 200, and >500 μM, respectively). PKSI-527 reduces bradykinin generation induced by kaolin and λ-carrageenan ex vivo in human plasma. It also prolongs partial thromboplastin and euglobulin clot lysis times. In vivo, PKSI-527 (300 mg/kg per day) reduces hyperplasia, pannus formation, and infiltration of inflammatory cells in the tarsal joint of mice with collagen-induced arthritis.{39443}  

 

Available on backorder

SKU: 23974 - 5 mg Category:

Description

An inhibitor of plasma kallikrein (Ki = 0.81 μM); reduces bradykinin generation induced by kaolin and λ-carrageenan ex vivo in human plasma; prolongs partial thromboplastin and euglobulin clot lysis times; reduces hyperplasia, pannus formation, and infiltration of inflammatory cells in the tarsal joint of mice with collagen-induced arthritis


Formal name: 4-[[(2S)-2-[[[trans-4-(aminomethyl)cyclohexyl]carbonyl]amino]-1-oxo-3-phenylpropyl]amino]-benzeneacetic acid, monohydrochloride

Synonyms: 

Molecular weight: 474

CAS: 128837-71-8

Purity: ≥95%

Formulation: A solid


Product Type|Biochemicals|Small Molecule Inhibitors|Blood Coagulation Factors||Product Type|Biochemicals|Small Molecule Inhibitors|Peptidases & Proteases||Research Area|Cardiovascular System|Blood|Thrombosis||Research Area|Immunology & Inflammation|Autoimmunity|Rheumatoid Arthritis